机构地区:[1]State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs,Artemisinin Research Center,and Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing,China [2]Department of Biological Sciences,National University of Singapore,Singapore [3]China Academy of Chinese Medical Sciences,Beijing,China
出 处:《Science of Traditional Chinese Medicine》2024年第1期20-28,共9页中医药科学(英文)
基 金:This research was funded by Establishment of Sino-Austria“Belt and Road”Joint Laboratory on Traditional Chinese Medicine for Severe Infectious Diseases and Joint Research(2020YFE0205100);National Natural Science Foundation of China(grant/award no.82204479);Guangdong Basic andApplied BasicResearch Foundation(grant/award no.2021A1515110381);Fundamental Research Funds for the Central public welfare research institutes(Grant No.ZZ14-YQ-056,ZZ13-YQ-103,ZZ16-ND-10-11,ZZ16-ND-10-03).
摘 要:Background:Acute respiratory distress syndrome induced by acute lung injury(ALI)is the main cause for the high mortality of coronavirus disease 2019(COVID-19).Huashi Baidu formula(HSBD)with the effects of eliminating dampness,clearing heat,ventilating lung,and removing toxin has been proven to be effective in the treatment of COVID-19,especially in severe cases.However,the underlying mechanism and target proteins of HSBD remain unclear.Objective:To provide evidence and decipher the mechanism of HSBD in alleviating inflammation and ALI.Materials and Methods:A mouse model of ALI was induced by lipopolysaccharide(LPS),and hematoxylin-eosin staining was used to examine the protective effects of HSBD on the model mice.The cellular thermal shift assay and proteomics analysis were used to predict the target proteins.Furthermore,the A549 cells with peroxiredoxin 5(PRDX5)knockdown were established to validate the predicted proteins.Results:Huashi Baidu formula treatment mitigated ALI and inflammatory cytokine dysfunction in LPS-induced mice,thus exerting a therapeutic effect on COVID-19.Huashi Baidu formula could serve as a therapeutic agent to alleviate inflammation and lung injury via nuclear factorκB and phosphatidylinositol 3-kinase signaling and interleukin 17 inhibition as well as targeting PRDX5,which could be one of the promising targets for treating inflammation.In the A549 cell line with PRDX5 knockdown(si-PRDX5),the anti-inflammation effects of HSBD,including reversing LPS-induced increase in the nitric oxide level and reduction in the hydrogen peroxide content,were attenuated.Thus,HSBD protected A549 cells from LPS-induced inflammation mainly by targeting PRDX5.Conclusions:Huashi Baidu formula alleviates ALI by targeting nuclear factorκB/phosphatidylinositol 3-kinase and PRDX5,as well as inhibiting the immune response induced by IL-17.
关 键 词:Huashi Baidu formula COVID-19 Lung injury Peroxiredoxin 5 NF-κB pathway
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...